Assignee
ENLIVEN THERAPEUTICS INC
US·1 granted patent·4 pending applications·0 citations·filing 2021–2023
Top patents by PatentIndex Score
5 records- 0166US11807649B2Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2ENLIVEN THERAPEUTICS INC·Filed 2022·Granted Nov 7, 2023·0 cites·44 claims
- 0265US2023382923A1Fused tetracyclic quinazoline derivatives as inhibitors of erbb2ENLIVEN THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0351US2024116921A1Lactam (hetero)arylfusedpyrimidine derivatives as inhibitors of erbb2ENLIVEN THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 0450US2024043420A17-azaindole compounds for inhibition of bcr-abl tyrosine kinasesENLIVEN THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 0550US2023265098A1Alkyne quinazoline derivatives as inhibitors of erbb2ENLIVEN THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when ENLIVEN THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →